



Advancing Neuroscience.

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne’s robust product suite offers acute diagnostic neurology and chronic treatment solutions for epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with two FDA-cleared product families: Evo® Cortical Electrodes and Evo® sEEG Electrodes. These electrodes offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation. NeuroOne recently received FDA-clearance for its third product family, OneRF®, a novel combination recording and radiofrequency (RF) ablation device. The Company is engaged in research and development for drug delivery and spinal cord stimulation (SCS) programs and is exploring potential applications of its medical technology with artificial intelligence.

Key Investment Considerations

- **Disruptive next-generation diagnostic electrodes** advancing a new era in neuroscience; foundational technology initially **developed in collaboration with Mayo Clinic**, a shareholder of the Company.
- **First-to-market combination ablation technology**; indication for both recording electrical activity and ablating nervous tissue.
- **Strategic collaboration with Zimmer Biomet** (NYSE:ZBH, ~\$25B mkt cap) for exclusive commercialization and distribution of EVO® diagnostic electrodes; payments of **\$5.5 million received** to date.
- Potential to penetrate **large disease populations and markets**: epilepsy (**\$1B+**), Parkinson’s disease (**\$5B+**), and SCS (**\$10B+**); licensing potential for applications in multiple related neurological disorders.
- Multi-billion market opportunity for **combination devices**; potential for technology adaptation utilizing **artificial intelligence**.
- **Leadership with deep expertise** in medical device technology, marketing, and business development; world-class board of directors; esteemed scientific and physician advisory boards.
- **Ample capital resources** to support upcoming commercial and development catalysts.

Key Partnerships

<p>Zimmer Biomet Agreement</p> <ul style="list-style-type: none"> ▪ Worldwide leader in orthopedics and robotic technology used in minimally invasive neurosurgeries ▪ Exclusive development and distribution agreement since 2020; \$5.5 million in licensing and milestone payments received ▪ Evo® sEEG electrode product line complementary to Zimmer’s ROSA ONE® Brain platform 		<p>Mayo Clinic Partnership</p> <ul style="list-style-type: none"> ▪ Mayo Clinic partnership with NeuroOne began in 2014 ▪ Mayo Clinic began testing Evo® technology in pre-clinical models and clinical research in 2015 ▪ First commercial human use of Evo® Cortical Electrodes performed at Mayo Clinic in November 2020 ▪ Mayo Clinic leading neurologist Dr. Greg Worrell chairs NeuroOne Scientific Advisory Board
--	---	---

Fiscal Year 2024 Potential Catalysts

- Evo® sEEG: revenue expected to increase with addition of new accounts by Zimmer Biomet and commercial launch of the OneRF™ Ablation System.
- OneRF™ Ablation System: limited commercial launch targeted for second calendar quarter of 2024.
- Exploration of additional strategic partnerships that could leverage core high-resolution, thin-film electrode technology.
- Exploration of new indications such as motor function, hypertension, high blood pressure, depression, and pain.

Market Snapshot

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
\$1.38 (3/4/24)	\$0.85 - \$2.07	210K	25.9M	\$35.7M

NeuroOne Medical Technologies Corporation | 7599 Anagram Drive Eden Prairie, MN 55344

Investor Relations Contact | 800-631-4030 | ir@nmtc1.com

Evo® Cortical Electrode* (less than 30-day use)

Thin-film electrode for the diagnosis of various neurological conditions. Evo's high-definition, minimally invasive technology delivers major advantages over widely used legacy silicone-based electrodes.

- 7 times thinner and 8 times lighter than typical silicone electrodes¹
- Reduced artifact and improved signal quality²
- Reduced inflammation based on published testing by Mayo Clinic³



Evo® sEEG Electrode* (less than 30-day use)

Stereoencephalography recording, spinal cord stimulation, brain stimulation and ablation solutions. The first clinical case use was performed intraoperatively by Dr. Robert Gross, Emory University for brain mapping at the subsurface level of the brain.

- Less invasive – reduced risk of brain plunge, may require fewer brain insertions
- Improved signal quality vs. other devices¹
- Proven implant accuracy¹
- Automated manufacturing, precise and consistent quality¹



*Caution U.S. Federal law restricts this device to sale by, or on the order of, a physician.

¹NeuroOne data on file ²Bower R., et al. December 2017. Multi-Resolution intracranial EEG rodent recording system. (Abst. 2.062) 2017. American Epilepsy Society ³Worrell, G. et al. December 2019. Commercial Scale Production of Thin-Film electrode arrays for Clinical Intracranial EEG. (Abst. 1.154), 2019. American Epilepsy Society)

OneRF™ Ablation System (510(k) application under FDA review)

Utilizes existing implanted sEEG diagnostic electrodes for RF ablation in nervous (brain) tissue to create tissue lesion(s). Safer and less expensive combination electrode, intended to improve patient outcomes, reduce procedures, and lower overall treatment cost.

- Less discomfort to patient
- More efficient for surgeon
- Potentially better pain targeting



Initial Target Markets

Epilepsy — caused by conditions that affect the brain: stroke, brain tumor, traumatic brain injury, and central nervous system infections. Estimated \$28B in annual costs.¹

Brain ablation — surgical removal of harmful brain tissue and tumors. Estimated \$100M+ global market, growing rapidly.

Chronic back pain (CBP) — caused by an estimated 80,000+ “failed” back surgeries per year in the U.S.²; prevalence of 3%+ in U.S. adult population. Estimated \$187B in two-year direct and indirect costs.³

Parkinson’s disease — disorder of the central nervous system caused by loss of brain cells. Estimated \$52B in annual direct and indirect costs.⁴

¹AJMC: [Examining the Economic Impact and Implications of Epilepsy](#) ²NIH: [Comparison among pain, depression, and quality of life...](#) ³University of Texas Libraries: [The economic burden of chronic back pain...](#) ⁴Parkinson’s Foundation [Statistics](#)

Leadership

Dave Rosa, President and CEO: Three decades of experience in the medical device industry; CEO roles with early-stage companies and senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical.

Ron McClurg, CFO: 30 years of financial leadership experience; CFO at Incisive Surgical, Wavecrest Corporation, Video Sentry Corporation, Insignia Systems, and Orthomet.

Chris Volker, COO: 20 years of medical device industry experience; senior leadership roles with Cardiovascular Systems and St. Jude Medical. Began his career in healthcare and technology investment banking.

Mark Christianson, Co-Founder, Business Development Director, Medical Sales Liaison: 15 years of executive sales, sales management, marketing, and project management experience with development stage companies.

Steve Mertens, CTO: SVP of R&D and Operations at Nuvara; SVP of R&D for Boston Scientific.

Hijaz Haris, VP of Marketing: 20 years of experience with Medtronic, the world’s largest medical device company.

Camilo Diaz Botia, Director of Electrode Development: Experienced neuroengineer; process engineering team leader for brain-computer interface technology at Neuralink Corp., founded by Elon Musk.

Chad Wilhelmy, VP Quality and Regulatory: 20 years of experience including leadership role at HLT, Inc.

Forward-Looking Statements: This fact sheet contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this fact sheet may be a forward-looking statement that reflects NeuroOne’s current views about future events. Forward-looking statements may include statements regarding the development of the Company’s electrode technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and commercialization of our technology, clinical and pre-clinical testing, business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Our actual future results may be materially different from what we expect due to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions and the impact of COVID-19, or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds; the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this fact sheet and NeuroOne undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.